Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.59 |
| ▸ | NPY1R | P25929 | 9/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.59 |
| ▸ | NPY2R | P49146 | 5/20 | 0.59 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14385894 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL16690639 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29947131 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29947199 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29947183 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL19267519 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL6366210 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL6362150 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL29707523 | 1.00 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL24121685 | 0.97 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | NPY4R 4751/4885NPY1R 4667/4885NPY5R 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.